Table 1.
Clinical and pathological characteristics of the five independent HNSCC cohorts. FAT1‐HR, FAT1‐associated high risk; FAT1‐LR, FAT1‐associated low risk; FHCRC, Fred Hutchinson Cancer Research Center; HNSCC, head and neck squamous cell carcinoma; KHUMC, Kyung Hee University Medical Center; MDACC, MD Anderson Cancer Center; NA, not available; TCGA, The Cancer Genome Atlas.
| Characteristics |
TCGA cohort (n = 566) |
Leipzig cohort (n = 270) |
FHCRC cohort (n = 97) |
MDACC cohort (n = 74) |
KHUMC cohort (n = 72) |
|---|---|---|---|---|---|
| Age | |||||
| ≥ 60 | 316 (55.83%) | 117 (43.33%) | 47 (48.45%) | 37 (50.00%) | 44 (61.11%) |
| < 60 | 249 (43.99%) | 153 (56.67%) | 50 (51.55%) | 37 (50.00%) | 27 (37.50%) |
| Unknown | 1 (0.18%) | 0 | 0 | 0 | 1 (1.39%) |
| Sex | |||||
| Male | 415 (73.32%) | 223 (82.59%) | 66 (68.04%) | 58 (78.38%) | 54 (75.00%) |
| Female | 151 (26.68%) | 47 (17.41%) | 31 (31.96%) | 16 (21.62%) | 18 (25.00%) |
| Smoking | |||||
| Yes | 425 (75.09%) | 222 (82.22%) | NA | 59 (79.73%) | 45 (62.50%) |
| No | 128 (22.61%) | 48 (17.78%) | NA | 15 (20.27%) | 25 (34.72%) |
| Unknown | 13 (2.3%) | 0 | NA | 0 | 2 (2.78%) |
| Alcohol | |||||
| Yes | 371 (65.55%) | 239 (88.52%) | NA | NA | NA |
| No | 182 (32.16%) | 31 (11.48%) | NA | NA | NA |
| Unknown | 13 (2.3%) | 0 | NA | NA | NA |
| Tumor site | |||||
| Oral cavity | 346 (61.13%) | 83 (30.74%) | 97 (100%) | 71 (95.95%) | 43 (59.72%) |
| Oropharynx | 82 (14.49%) | 102 (37.78%) | 0 | 3 (4.05%) | 11 (15.28%) |
| Larynx | 128 (22.61%) | 48 (17.78%) | 0 | 0 | 18 (25.00%) |
| Hypopharynx | 10 (1.77%) | 33 (12.22%) | 0 | 0 | 0 (%) |
| Unknown | 0 | 4 (1.48%) | 0 | 0 | 0 (%) |
| T classification | |||||
| T1–T2 | 218 (38.52%) | 115 (42.59%) | NA | 30 (40.54%) | 33 (45.83%) |
| T3–T4 | 344 (60.78%) | 155 (57.41%) | NA | 44 (59.46%) | 30 (41.67%) |
| Unknown | 4 (0.71%) | 0 | NA | 0 | 9 (12.50%) |
| N classification | |||||
| Negative | 295 (52.12%) | 94 (34.81%) | NA | 42 (56.76%) | 35 (48.61%) |
| Positive | 267 (47.17%) | 176 (65.19%) | NA | 32 (43.24%) | 29 (40.28%) |
| Unknown | 4 (0.71%) | 0 | NA | 0 | 8 (11.11%) |
| Stage | |||||
| I–II | 135 (23.85%) | 55 (20.37%) | 41 (42.27%) | 19 (25.68%) | 24 (33.33%) |
| III–IV | 417 (73.67%) | 215 (79.63%) | 56 (57.73%) | 55 (74.32%) | 30 (41.67%) |
| Unknown | 14 (2.47%) | 0 | 0 | 0 | 18 (25.00%) |
| HPV status | |||||
| Positive | 21 (3.71%) | 60 (22.22%) | 0 (%) | NA | 3 (4.17%) |
| Negative | 65 (11.48%) | 209 (77.41%) | 97 (100%) | NA | 15 (20.83%) |
| Unknown | 480 (84.81%) | 1 (0.37%) | 0 | NA | 54 (75.00%) |
| Radiotherapy | |||||
| Yes | 304 (53.71%) | NA | NA | 47 (63.51%) | 43 (59.72%) |
| No | 171 (30.21%) | NA | NA | 26 (35.14%) | 27 (37.50%) |
| Unknown | 91 (16.08%) | NA | NA | 1 (1.35%) | 2 (2.78%) |
| Treatment | |||||
| Unimodal | 78 (28.89%) | 43 (44.33%) | 25 (33.78%) | 31 (43.06%) | |
| Multimodal | 189 (70.00%) | 53 (54.64%) | 48 (64.87%) | 41 (56.94%) | |
| Palliative | 3 (1.11%) | 0 | 0 | 0 | |
| Unknown | 0 | 1 (1.03%) | 1 (1.35%) | 0 | |
| FAT1 signature | |||||
| FAT1‐LR | 195 (34.45%) | 101 (37.41%) | 31 (31.96%) | 19 (25.68%) | 27 (37.5%) |
| FAT1‐HR | 371 (65.55%) | 169 (62.59%) | 66 (68.04%) | 55 (74.32%) | 45 (62.5%) |